Lack of pharmacokinetic interaction between derazantinib and naringin in rats

CONTEXT: Derazantinib—an orally bioavailable, ATP competitive, multikinase inhibitor—has strong activity against fibroblast growth factor receptors (FGFR)2, FGFR1, and FGFR3 kinases. It has preliminary antitumor activity in patients with unresectable or metastatic FGFR2 fusion-positive intrahepatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ya-nan, Chen, Jie, Xu, Xinhao, Hu, Yingying, Hu, Jin-yu, Xu, Ren-ai, Lin, Guanyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013357/
https://www.ncbi.nlm.nih.gov/pubmed/36891628
http://dx.doi.org/10.1080/13880209.2023.2185641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013357/
https://www.ncbi.nlm.nih.gov/pubmed/36891628
http://dx.doi.org/10.1080/13880209.2023.2185641

Ejemplares similares